Acknowledgments
This study was funded by GlaxoSmithKline (GSK). GSK contributed to study design, implementation, data collection, interpretation, and analysis. All authors had full access to the data upon request and had final responsibility for the decision to submit for publication.
Medical writing support was provided by Emily Mercadante, PhD, of Fishawack Indicia Ltd., UK, part of Fishawack Health, funded by GSK.
Author contributions
LMS, HH, JRG, LWE, and SJI contributed to the conception or design of the study. LMS, HH, MCL, EH, HI, CAS-M, JR, LWE, and SJI contributed to the acquisition of data. All authors were involved in data analysis or interpretation. LMS and SJI had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Conflict of interest disclosures
LMS reports personal fees from Novartis, Puma, Lumicell, and Avrobio; travel support from Tesaro and Merck; research funding to institution from Tesaro and Merck. HH reports research funding to institution from Arvinas, AbbVie, Bristol-Myers Squibb, Daiichi Pharma, GSK, Karyopharm, Prescient, G1 Therapeutics, Marker Therapeutics, Novartis, Horizon Pharma, Quantum Leap Healthcare Collaborative, Pfizer, Zymeworks and Seattle Genetics; grants from Department of Defense; personal fees from Speaker’s Bureau for Lilly. MCL reports research funding to institution from Eisai, Exact Sciences, Genentech, Genomic Health, GRAIL, Menarini Silicon Biosystems, Merck, Novartis, Seattle Genetics, and Tesaro; funding to institution for participation in advisory boards for Celgene, Roche/Genentech, Genomic Health, GRAIL, Ionis, Merck, Pfizer, Seattle Genetics, and Syndax. EH reports research funding to institution from OncoMed, Genentech/Roche, Zymeworks, Rgenix, ArQule, Clovis, Silverback Therapeutics, Millennium, Medivation, Acerta Pharma, Sermonix Pharmaceuticals, Aravive, Torque, Black Diamond, Karyopharm, Infinity Pharmaceuticals, Curis, Syndax, Novartis, Boehringer Ingelheim, Immunomedics, Fujifilm, Taiho, Deciphera, Fochon, Molecular Templates, Onconova Therapeutics, Dana Farber Cancer Hospital, Hutchinson Medipharma, MedImmune, Seagen, Puma Biotechnology, Compugen, TapImmune, Lilly, Pfizer, H3 Biomedicines, Takeda, Merus, Regeneron, Arvinas, StemcentRx, Verastem, eFFECTOR Therapeutics, CytomX, InventisBio, Lycera, Mersana, Radius Health, AbbVie, Nucana, Leap Therapeutics, Zenith Epigenetics, Harpoon, Orinove, AstraZeneca, Tesaro, Macrogenics, EMD Serono, Daiichi Sankyo, Syros, Sutro, GI Therapeutics, Merck, PharmaMar, Olema, Polyphor, Immunogen, Plexxikon, and Amgen; fees for consulting/advisory role to institution from Genentech/Roche, Boehringer Ingelheim, Novartis, Dantari, Lilly, Merck, Puma Biotechnology, Silverback Therapeutics, CytomX, Pfizer, Mersana, Black Diamond, H3 Biomedicine, Daiichi Sankyo, and AstraZeneca; travel/accommodation expenses from AstraZeneca, Lilly, Pfizer, Puma, and Daiichi Sankyo. HI has no conflicts of interest to report. CAS-M reports grants from Pfizer, AstraZeneca, and Bristol-Myers Squibb; research funding to institution from Novartis; advisory boards for Bristol-Myers Squibb, Seattle Genetics, Athenex, and Genomic Health. JR reports grants to institution from Eli Lilly, Tesaro, Sarah Cannon, TG Therapeutics, Genentech, Celgene, Merck, Bristol-Myers Squibb, Boston Biomedical Inc., AstraZeneca, Novocure, Calithera Biosciences, Novartis, Guardant Health, Acerta Pharma, Rhizen Pharmaceuticals, Takeda Pharmaceuticals, Onconova Therapeutics, Sanofi, and CTI Biopharma; grants from Daiichi Sankyo, Seattle Genetics, Taiho Oncology, Odonate, Boehringer Ingelheim, Macrogenics, Ipsen/Medpace, Beigene, Acerta, Verastem, Pharmacyclics, Medimmune, Jiangsu Hengrui Med, Arcus Biosciences, Calethera, Mirati, Pfizer, Immunogen, Karyopharm, and GlaxoSmithKline; speaker bureau fees and travel expenses from Eisai and Janssen; personal fees for advisory boards for Karyopharm, Polyphor, and Bayer. PP, MS, SH, and YT are employees of and owners of shares/options in GlaxoSmithKline. JRG is an employee of and owner of shares/options in GlaxoSmithKline; reports stock ownership in Pfizer. LWE has no conflicts to report. SJI reports personal fees for consulting from AbbVie, Hengrui, Immunomedics, Mylan, Myriad, Puma, Seattle Genetics, and Novartis.